Titre de l'étude
Follow-up to the AVANT study up to 8 and 10 years (median follow up) in patients with colon carcinoma
Promoteur
GERCOR 151 rue du Faubourg St Antoine 75011 PARIS – France
Investigateur Coordonateur
Service : -
Email:
ARC Coordonnateur
NellyROLDAN
Email: nelly.roldan@gercor.com.fr
Objectif principal
Overall Survival (OS) of the stage III population randomized in the AVANT study
Objectifs secondaires
- OS in stage III alive patients not lost to follow up at 8 years median follow up
- OS in stage II patients
- OS and DFS in elderly patients
- OS after relapse and management of relapse
- Disease-Free Survival
- Relapse-Free Survival
- Cancer Specific Survival
- Time to Relapse
- Second cancer rate
- Co-morbidities
- Prognostic factors
Nombre de patients
Un total de3000 patients est à inclure pour l’analyse finale.
Population de l’étude
Principaux critères d’inclusion
- All patients randomized in the AVANT trial (3451 patients).
Principaux critères de non inclusion
- Patients opposed to the collection of their medical data (The use of a new ICF will depend on local regulatory requirements).
Documents de l'étude en accès réservé aux investigateurs
